- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02358083
Attitudes Toward Human Papillomavirus and Influenza Vaccination Among Mothers of Early Adolescents
October 28, 2023 updated by: Gregory Zimet, Indiana University
The purpose of this study was to determine whether messages about 1. relative risk of vaccination vs. other activities and 2. strength of doctor's recommendation influenced parental intention to get own child vaccinated against human papillomavirus (HPV) or Influenza.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
1165
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- 18 years of age or older
- Lives in United States
- Mother or female legal guardian of at least one child aged 9-13
- Able to understand English
- For HPV condition: Target child must not have received any doses of HPV vaccine
- For Flu condition: Target child must not have received the flu vaccine during the prior flu season
Exclusion Criteria:
- Under 18 years of age
- Not mother or female legal guardian of at least one child ages 9-13
- Not living in United States
- Not able to understand English and Spanish
- For HPV condition: Target child had already received at least 1 dose of the HPV vaccine
- For Flu condition: Target child received the influenza vaccine during the previous flu season
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Arm 1. HPV + Control + Control
HPV is target vaccine.
No message regarding relative safety of vaccine; Provider provides brief routine recommendation for vaccination.
|
|
Experimental: Arm 2. HPV + Control + Strong
HPV is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination.
|
There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.
|
Experimental: Arm 3. HPV + Control + Disclosure
HPV is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
|
There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.
|
Experimental: Arm 4. HPV + Safety + Control
HPV is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides brief routine recommendation for vaccination.
|
There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.
|
Experimental: Arm 5. HPV + Safety + Strong
HPV is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination.
|
There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.
|
Experimental: Arm 6. HPV + Safety + Disclosure
HPV is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
|
There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.
|
No Intervention: Arm 7. Flu + Control + Control
Flu is target vaccine.
No message regarding relative safety of vaccine; Provider provides brief routine recommendation for vaccination.
|
|
Experimental: Arm 8. Flu + Control + Strong
Flu is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination.
|
There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.
|
Experimental: Arm 9. Flu + Control + Disclosure
Flu is target vaccine; No message regarding relative safety of vaccine; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
|
There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.
|
Experimental: Arm 10. Flu + Safety + Control
Flu is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides brief routine recommendation for vaccination.
|
There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.
|
Experimental: Arm 11. Flu + Safety + Strong
Flu is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination.
|
There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.
|
Experimental: Arm 12. Flu + Safety + Disclosure
Flu is target vaccine; Provider provides message about relative safety of vaccination compared to other common daily activities; Provider provides strong recommendation for vaccination and personal disclosure regarding own child's vaccination history.
|
There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Willingness to vaccinate child with target vaccine
Time Frame: During survey administration, at approximately 15 minutes into the survey.
|
During survey administration, at approximately 15 minutes into the survey.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Gregory D Zimet, PhD, Indiana University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2014
Primary Completion (Actual)
August 1, 2014
Study Completion (Actual)
August 1, 2014
Study Registration Dates
First Submitted
February 3, 2015
First Submitted That Met QC Criteria
February 5, 2015
First Posted (Estimated)
February 6, 2015
Study Record Updates
Last Update Posted (Actual)
October 31, 2023
Last Update Submitted That Met QC Criteria
October 28, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 8645194
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza Vaccines
-
University of MichiganCompletedInfluenza VaccinesUnited States, Canada
-
Centers for Disease Control and Prevention, ChinaRecruitingPneumococcal Vaccines | Safety | Influenza Vaccines | COVID-19 Vaccines | Immunogenicity, VaccineChina
-
Imperial College LondonPublic Health EnglandCompletedInfluenza VaccinesUnited Kingdom
-
GlaxoSmithKlineCompletedInfluenza | Influenza VaccinesTaiwan, Hong Kong, Thailand, Singapore
-
Abbott BiologicalsQuintiles, Inc.CompletedInfluenza VaccinesCzech Republic, Estonia, Lithuania
-
GlaxoSmithKlineCompletedInfluenza | Influenza VaccinesUnited States
-
US Department of Veterans AffairsSt. Louis UniversityWithdrawnAged | Influenza VaccinesUnited States
-
GlaxoSmithKlineTerminatedInfluenza | Influenza VaccinesSpain
-
GlaxoSmithKlineCompletedInfluenza | Influenza VaccinesGermany
-
GlaxoSmithKlineCompletedInfluenza VaccinesCanada
Clinical Trials on Provider Communication about Vaccination
-
University of Massachusetts, WorcesterBoston University; National Heart, Lung, and Blood Institute (NHLBI)WithdrawnCovid19 | Vaccination
-
University of Southern CaliforniaNational Psoriasis FoundationCompletedPsoriasis | Atopic Dermatitis | AcneUnited States
-
US Department of Veterans AffairsCompleted
-
Children's Hospital of PhiladelphiaCompleted
-
Oslo University HospitalUniversity of Oslo; Columbia University; University Hospital of North Norway; Marshfield... and other collaboratorsCompleted
-
University of ThessalyRecruitingChronic Musculoskeletal PainGreece
-
Southcentral FoundationUniversity of Colorado, Denver; University of Washington; Washington State University and other collaboratorsCompletedAdvance Care PlanningUnited States
-
University of Alabama at BirminghamRecruitingHPV VaccinationUnited States
-
Norwegian Institute of Public HealthCity of Oslo, NorwayRecruiting
-
Children's Mercy Hospital Kansas CityUniversity of Kansas Medical Center; Midwest Cancer AllianceCompletedCommunication | Meningitis, Meningococcal | Satisfaction | Human Papilloma Virus | Tdap - Tetanus, Diphtheria and Acellular Pertussis VaccinationUnited States